BRTX-100 Cell Therapy for Chronic Lumbar Disc Disease

BRTX-100 Cell Therapy for Chronic Lumbar Disc Disease
81%55%30%Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 26 • YES 38.0%Apr 27 • YES 49.0%Apr 28 • YES 53.5%Apr 29 • YES 49.0%Apr 30 • YES 49.0%May 1 • YES 49.0%May 2 • YES 49.4%May 3 • YES 49.4%May 4 • YES 49.8%May 5 • YES 67.9%May 6 • YES 38.0%May 7 • YES 72.4%May 13 • YES 69.9%
BioRestorative Therapies ($BRTX)
No stock closeNo stock close$0.30$0.22$0.14Apr 26Apr 27Apr 28Apr 29Apr 30May 1May 2May 3May 4May 5May 6May 7May 8May 9May 10May 11May 12May 13Apr 27 • BRTX $0.23Apr 28 • BRTX $0.22Apr 29 • BRTX $0.20Apr 30 • BRTX $0.23May 1 • BRTX $0.23May 4 • BRTX $0.24May 5 • BRTX $0.25May 6 • BRTX $0.24May 7 • BRTX $0.23May 8 • BRTX $0.21May 11 • BRTX $0.20May 12 • BRTX $0.20May 13 • BRTX $0.19

Will this trial show a positive result on Primary Efficacy Endpoint: Clinical response, defined as at least a 30% decrease in pain as measured on the VAS scale and at least a 30% increase in function based on the ODI at Week 52 as compared to baseline?

Paper Trading
Create account to trade
ClinicalTrialModel PositionsModel ReasoningOracle
Primary Completion
12/1/26
Study Completion
12/1/27
Sponsor
BioRestorative Therapies
Ticker
$BRTX
Type
Phase 2
Trial Status
Recruiting
Trial Size
99
NCT
NCT04042844
Trial Description
This trial tests BRTX-100 cell injection for adults with chronic lumbar disc disease, measuring safety and pain and back-function improvement.